Product
EA3571 for Obesity and MASH Treatment
EA3571 is an orally available, potent dual inhibitor of enteropeptidase and trypsin, poised for Phase 2 trials in obesity and MASH.
EA Pharma is a subsidiary of Eisai as a specialty pharma in gastrointestinal (GI) space mainly Japanese market. In addition, we have provided constipation drug to psychiatrists. So, we are seeking for in-licensing opportunities in GI and psychiatry. Additionally, we are seeking out-licensing opportunities for our novel drug targeting obesity and MASH.
Business Domain / 分野
Business Type / 業種
Modalities / モダリティ
Disease Area / 疾患領域
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術
Product
EA3571 for Obesity and MASH Treatment
EA3571 is an orally available, potent dual inhibitor of enteropeptidase and trypsin, poised for Phase 2 trials in obesity and MASH.